There is evidence that CMV may be transmitted by transfusion of white blood cells which harbor viruses. Frozen reconstituted RBC are virtually free of leukocytes. This prospective study randomly selects neonates requiring blood transfusions. Group A infants received frozen reconstituted RBC, Group B reqular blood with negative CMV titer and qroup C regular blood with positive CMV titers. Maternal, umbilical cord and donor's blood were tested for CMV complement fixation titers. Follow-up serologic studies were carried out at 8 and 18 weeks.Urine was cultured for CMV at birth and at the same follow-up schedule. Transfusion acquired infection is defined as seroconversion, a rising titer or a positive urine culture at 8 to 18 week follow-up period.
There is evidence that CMV may be transmitted by transfusion of white blood cells which harbor viruses. Frozen reconstituted RBC are virtually free of leukocytes. This prospective study randomly selects neonates requiring blood transfusions. Group A infants received frozen reconstituted RBC, Group B reqular blood with negative CMV titer and qroup C regular blood with positive CMV titers. Maternal, umbilical cord and donor's blood were tested for CMV complement fixation titers. Follow-up serologic studies were carried out at 8 and 18 weeks.Urine was cultured for CMV at birth and at the same follow-up schedule. Transfusion acquired infection is defined as seroconversion, a rising titer or a positive urine culture at 8 to 18 week follow-up period.
10 (25) p<O.005 None of 43 group A and 13 group B infants showed seroconversion or rising titer, while 10 of 40 group C infants did. Comparing those infected vs non-infected infants in group C, it became obvious that those who have received blood with higher CMV titer (>1:32) have significantly lower risk of infection (25%)cornpared to those who have received blood with lower CMV titer (risk >75%). knplcl l I l n srd g n t a n l c l n I n cmblnatlon accelerate k l l Ilng of g w p B streptococci (GBS) I n vltro. Penlcl l I1 n-amlnogl ycoslde cmblnatlons have been recmmrded for the treatment of GBS men1 rgl t l s despl t e poor penetrat l o n of the amlnogl ycosldes I n t o the cerebrospinal f luld. Prevlars studles have demonstrated accelerated kl 1 l l ng of GBS by cmbl natlons of penlcl l 1 1 n o r amplcll l l n ard gntamlcln. These studles u t l llzed concentratlons of anlncglycmldes not conslstentl y attainable I n the CSF f o l l a l n g systenlc ajmlnlstratlon. We examlned 20 strains o f GBS for accelerated k l l llng x l t h g n t a n l c l n concentratlons attainable I n the concentrations cmparable t o those attained I n the CSF. These flndlngs p r w l d e a ratlonale for the use of a cmblnatlon of a peolcl I l l n ard g n tamlcln I n t r e a t l n g 685 m n l n g l t l s I n splte of "subtherapeutlc" levels of g n t a n l c l n I n the CSF.
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The pneumcoccus is the pathogen recovered most often from blood cultures in our hospital. We identified 205 episodes of systemic pneumococcal infections in 201 children during a 34 mo. period. There were 54 infections in 1978 (10 months), 64 in 1979 and 87 in 1980. The frequency of infections was highest in May and April (mean number of episodes/month 10.3 and 9.3 respectively) and was lowest in August and September (1.3 and 1.6). Children with pneumococcal infection ranged in age from 1 month to 14 years (mean age of 20 months). There were 126 boys and 75 girls. Seventy six percent of the children were black. Occult bacteremia (128 episodes) was the most frequently seen illness. There were 40 instances of pneumonia with bacteremia, 31 of meningitis, 4 of cellulitis and 2 of septic arthritis. Three children had recurrent infections: one with sickle cell anemia had three separate episodes caused by type 23F despite having received pneumococcal vaccine. Four children died: two had meningitis, one (asplenic child) had bacteremia and one (with myocarditis) had bacteremic pneumonia. One hundred thirty isolates were serotyped. During a 19 day period in 1982, 4 of 12 infants in an NICU room at the University of Illinois developed hyperbilirubinemia with or without thrombocytopenia, fever or respiratory distress. Each of the 4 infants was viruric with CMV. All 4 were premature (gestational ages 26-31 weeks), were at least 1 month old at onset of symptoms (range 36-79 days) and had received multiple transfusions of packed red blood cells (range 4-11 transfusions; 94-150 cc total volume). Although the mothers of all 4 infants had IgG to CMV, none had anti-CMV IgM; cervical cultures were obtained from 2 of the 4 mothers, and CMV was not recovered.
BamHl restriction-endonuclease analysis of all 4 CMV isolates showed identical banding patterns in the CMV's of 2 infants who had received blood from a common donor. The other 8 infants were followed for acquisition of CMV; none developed viruria. Of the 11 female health-care personnel in closest contact with the CMVinfected infants, 2 had anti-CMV IgG, but neither showed rises in titer or developed anti-CMV IgM. The other 9 remained seronegative 1 month following their exposure. Restriction-endonuclease analysis, used here in conjunction with conventional epidemiology indicates a low risk of CMV transmission from infected, tertiarycare NICU infants to other neonates or to health-care personnel.
ENHANCED IMMUNOGENICITY I N YOUNG INFANTS OF A NEW HAEMOPHILUS INFLUENZAE TYPE B(HIB) CAPSULAR POLYSAC-" 150 CHARIDE(PRP)-DIPHTHERIA TOXOID(D) CONJUGATE VACCINE.
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To enhance t h e immune reipotise t o PEP i n young infants,-we employed a conjugate vaccine whose synthesis i s based upon t h e hapt e n -c a r r i e r p r i n c i p l e f o r inducing T -c e l l immune responses. PRP was c o v a l e n t l y coupled t o D t o make t h e PRP-D conjugate vaccine.
To evaluate immunogenicity and s a f e t y i n t h e c r u c i a l age group <6months we e n r o l l e .05, 0.4, 0.8, 3.3, 4 .6 and 13.5ug/ml. P r e l i m i n a r y ELISA data suggests t h e h i g h e s t responses were IgG. There was no d i f f e r e n c e i n r e a c t i o n r a t e s ( l o c a 1 o r systemic) between PRP-D o r s a l i n e groups.
I n t h e p o p u l a t i o n o f young i n f a n t s a t g r e a t e s t HIB disease r i s k , PRP-D appears t o be safe and have enhanced immunogenicity. Presence o f an AB boost and IgG AB suggests a T -c e l l a m p l i f i c a ti o n o f t h e PRP immune response w i t h conjugate vaccines. household contacts daycare center contacts, Eskimo and I n d i a n i n f a n t s , s i c k l e c e l l and immunocompromised p a t i e n t s . HIG, prepared from pooled sera o f a d u l t s immunized w i t h PRP, contains a 10-20 f o l d increase i n anti-PRP AB ( 6 0 0~g / m l ) compared t o standard I.G.
To evaluate t h e s a f e t y and pharmacokinetics of HIG, we gave 2 doses t o 14 i n f a n t s a t 2 and 6 mos. o f age. The GMT anti-PRP AB l e v e l s measured by RIA(ng/ml) were: There was l i t t l e v a r i a b i l i t y i n dose response. Assuming a p r o t e c t i v e l e v e l o f 150ng/ml, t h e low dose and h i q h dose regimens would be expected t o provide 3 mos. and 4 mos. p r o t e c t i o n , respect i v e l y . No adverse e f f e c t s were observed and immune responses t o tetanus a t 7 mos. were s i m i l a r i n HIG r e c i p i e n t s and c o n t r o l s .
Passive p r o p h y l a x i s f o r HIB disease w i t h HIG o f f e r s an a t t r a ct i v e approach t o p r o t e c t i n g h i g h r i s k groups u n t i l e f f e c t i v e a c t i v e immunization i s possible.
